0001356090
false
0001356090
2023-08-09
2023-08-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 9, 2023
Precigen,
Inc.
(Exact name of registrant as specified in its
charter)
Virginia |
|
001-36042 |
|
26-0084895 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
20374 Seneca Meadows Parkway, Germantown, Maryland
20876
(Address of principal executive offices) (Zip
Code)
(301) 556-9900
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, No Par Value |
|
PGEN |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02. |
Results of Operations and Financial Condition. |
Attached as Exhibit 99.1 is a copy of a press release of Precigen,
Inc., dated August 9, 2023, reporting its financial results for the quarter ended June 30, 2023.
This information, including the Exhibit attached hereto, shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 7.01. |
Regulation FD Disclosure. |
Attached as Exhibit 99.2 is a copy of a press release of the Company,
dated August 9, 2023, providing an overview of certain research and development updates. This information, including the Exhibit attached
hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference
in such filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Precigen, Inc. |
|
|
|
|
By: |
/s/ Donald P. Lehr
|
|
|
Donald P. Lehr |
|
|
Chief Legal Officer |
Dated: August 9, 2023
Exhibit 99.1
Precigen Reports Second Quarter and First Half
2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway
into 2025
– The FDA confirmed that the ongoing Phase 1/2 single arm study of
PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no additional randomized, placebo-controlled
trial will be required to support submission of a BLA – |
– Company to prioritize portfolio activities to accelerate PRGN-2012
and continue advancement of other key programs, by implementing strategies to reduce clinical costs (e.g., reducing CRO costs
without internal R&D headcount reduction) and reduce SG&A costs – |
– Completely retired the outstanding balance of convertible notes
– |
– Cash, cash equivalents, short-term and long-term investments totaled
$95.6 million as of June 30, 2023; cash runway projected into 2025 – |
GERMANTOWN, MD, August 9, 2023 –
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2023 financial results
and business updates.
"Today we announced that the FDA confirmed
the ongoing Phase 1/2 study of PRGN-2012 will serve as the pivotal study to support accelerated approval, an important milestone that
brings Precigen a step closer in our transition to a commercial stage company and in realizing our vision of bringing life-changing therapies
to patients with unmet medical need. We look forward to working with the FDA to submit a BLA and potentially bringing the first drug therapy
for RRP patients. As a result of this exciting milestone, we are prioritizing our portfolio activities to maximize the potential success
of PRGN-2012 while continuing to strategically advance other key programs,” said Helen Sabzevari, PhD, President and CEO of Precigen.
“We have built a strong portfolio based on the AdenoVerse and UltraCAR-T platforms and continue to advance important programs with
a focus on agility, efficiency and commercial viability.”
“As
a result of our capital raise in January, our portfolio prioritization and other cost-saving measures, including completely retiring our
convertible notes, the Company’s balance sheet is well positioned for the future,”
said Harry Thomasian Jr., CFO of Precigen. "These measures have enabled us to extend our projected cash runway into 2025, exclusive
of non-dilutive strategies, including strategic partnerships, which could extend our cash runway further."
Program Highlights
PRGN-2012 AdenoVerse™
Immunotherapy in RRP
| · | The Company announced that the
the US Food and Drug Administration (FDA) has agreed
that the ongoing Phase 1/2 single arm study of the first-in-class investigational PRGN-2012 AdenoVerse™ immunotherapy
for the treatment of recurrent respiratory papillomatosis (RRP) will serve as pivotal for the purpose of filing an accelerated approval
request for licensure. The FDA also confirmed no additional randomized, placebo-controlled trial will be required to support submission
of a biologics license application (BLA). Based on the FDA guidance, the Company also plans to initiate a confirmatory study prior to
submission of the BLA. |
| · | PRGN-2012 is an investigational off-the-shelf
AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV
11 for the treatment of RRP. |
| · | The Company completed
enrollment and dosing in the Phase 2 portion of the study (N=23) bringing the total number of enrolled patients to 35 at the recommended
Phase 2 dose. Patient follow up is currently ongoing and data collection is anticipated to be completed by the second quarter of 2024. |
| · | The
Company announced that the
FDA granted Breakthrough Therapy Designation for PRGN-2012 for
the treatment of RRP, adding to the existing Orphan
Drug Designation. The Breakthrough designation is based on |
positive Phase 1 clinical data that
showed that 50% of adult RRP patients (who had ≥3 surgeries to treat the disease in the year prior treatment) were "surgery-free"
(Complete Response) after PRGN-2012 treatment during the 12 month follow-up. All complete responders continue to be surgery-free with
a minimum follow-up of 18 months post-treatment.
PRGN 2009 AdenoVerse™
Immunotherapy in HPV-associated Cancers
| · | PRGN-2009 is an investigational off-the-shelf
AdenoVerse immunotherapy designed to activate the immune system to recognize and target HPV-positive solid tumors. |
| · | The
Company completed the Phase 1 study and presented
positive Phase 1 clinical data from
the monotherapy (N=6) and combination therapy (N=11) arms in patients with recurrent or metastatic
HPV-associated cancers at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
PRGN-2009 was safe and well-tolerated with only Grade 1 or 2 treatment related adverse events
and resulted in a 30% objective response rate (ORR) in the combination arm in patients with
heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint
blockade with prolonged duration of responses. |
| · | Enrollment was completed in the Phase 2 monotherapy
arm with 20 evaluable patients in newly diagnosed oropharyngeal squamous cell carcinoma (OPSCC) patients. |
| · | The
Company announced that the FDA
has cleared the Investigational New Drug (IND) application
to initiate a Phase 2 study of PRGN-2009 in combination with pembrolizumab in patients with
recurrent or metastatic cervical cancer. The Phase 2 randomized, open-label, two-arm study
will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab versus
pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer who are
pembrolizumab resistant. |
PRGN-3006 UltraCAR-T®
in AML
| · | PRGN-3006
is an investigational multigenic, autologous chimeric antigen receptor T (CAR-T) cell therapy
engineered to express a CAR specifically targeting CD33, membrane bound IL-15 (mbIL15), and
a kill switch. The FDA granted Orphan
Drug Designation and
Fast Track
Designation for
PRGN-3006 UltraCAR-T for patients with relapsed or refractory acute myeloid leukemia (AML). |
| · | The
Company completed
the Phase 1 dose escalation study and announced positive data at
the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. PRGN-3006 was
well-tolerated with no dose-limiting toxicities. A single infusion of autologous PRGN-3006
cells resulted in a 27% ORR in heavily pre-treated relapsed or refractory AML patients infused
following lymphodepletion. A single infusion of UltraCAR-T cells with or without lymphodepletion
demonstrated robust expansion and persistence in blood and bone marrow and PRGN-3006 infusion
with lymphodepletion resulted in a decrease in bone marrow blasts in 60% of heavily pre-treated
patients. |
| · | The Phase 1b dose expansion study of PRGN-3006
is ongoing and an interim clinical data presentation is expected in 2024. |
PRGN-3005 UltraCAR-T®
in Ovarian Cancer
| · | PRGN-3005 UltraCAR-T is an investigational multigenic,
autologous CAR-T cell therapy engineered to express a CAR specifically targeting the unshed portion of MUC16, mbIL15, and a kill switch. |
| · | The
Company completed the Phase 1 dose escalation cohorts of the intraperitoneal (IP) and intravenous
(IV) arms without lymphodepletion as well as in the lymphodepletion cohort in the IV arm
and presented
positive Phase 1 clinical data in
patients with advanced platinum resistant ovarian cancer at the 2023 ASCO Annual Meeting.
PRGN-3005 was well-tolerated with no dose-limiting toxicities, no cytokine release syndrome
(CRS) greater than Grade 2, and no neurotoxicity. PRGN-3005 cells demonstrated expansion
and persistence when delivered via either IP or IV infusion without lymphodepletion or via
IV infusion after lymphodepletion. A single IV infusion following lymphodepletion decreased
tumor burden in 67% of the heavily pretreated patients (median of 8 or more prior therapies). |
| · | The Phase 1b dose expansion study
of PRGN-3005 is ongoing. |
PRGN-3007 UltraCAR-T®
in Advanced ROR1+ Hematological and Solid Tumors
| · | PRGN-3007, based on the next generation of the
UltraCAR-T platform, is an investigational multigenic, autologous CAR-T cell therapy engineered to express a CAR targeting receptor tyrosine
kinase-like orphan receptor 1 (ROR1), mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene expression. |
| · | The Phase 1 dose escalation part of the Phase
1/1b study is ongoing. The target patient population for the Phase 1/1b study includes hematological cancers (chronic lymphocytic leukemia
(CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL)) and solid tumors (triple
negative breast cancer (TNBC)). |
Financial Highlights
| · | Completely retired the outstanding
balance of convertible notes in the second quarter. |
| · | Cash, cash equivalents, short-term and long-term investments
totaled $95.6 million as of June 30, 2023. |
| · | Selling, general, and administrative (SG&A)
costs decreased versus the prior year, by 27% and 21% for the three and six months ended June 30, 2023, respectively. |
Second Quarter 2023 Financial Results Compared
to Prior Year Period
Research
and development expenses decreased $0.1 million, or 0.7%, compared to the three months ended June 30, 2022. This decrease was primarily
driven by reduced spending on preclinical research programs.
SG&A
expenses decreased $3.4 million, or 27%, compared to the three months ended June 30, 2022. This decrease was primarily driven by a reduction
in professional fees of $2.2 million, due to decreased legal fees associated with certain litigation matters, as well as a $1.1 million
reduction in salaries, benefits, and other personnel costs due to reduced head count.
Revenues
decreased $1.1 million, or 39%, compared to the three months ended June 30, 2022. This decrease was related to reductions in services
performed at Exemplar.
Total other
income, net, increased $2.7 million compared to the three months ended June 30, 2023. This was primarily due to reduced interest expense
associated with the Company’s convertible notes as they were retired in the second quarter of 2023, and increased interest income
due to higher interest rates on investments.
Loss from
continuing operations was $20.3 million, or $(0.08) per basic and diluted share, compared to loss from continuing operations of $26.1
million, or $(0.13) per basic and diluted share, in Q2 2022.
First Half 2023 Financial Results Compared to
Prior Year Period
Research
and development expenses increased $0.3 million, or 1.2%, compared to the six months ended June 30, 2022. This increase was primarily
driven by a continued prioritization of clinical product candidates, offset by reduced spending on preclinical research programs.
SG&A
expenses decreased $5.4 million, or 21%, compared to the six months ended June 30, 2022. This decrease was primarily driven by a reduction
in professional fees of $4.2 million, due to decreased legal fees associated with certain litigation matters, as well as a $1.1 million
reduction in salaries, benefits, and other personnel costs due to reduced head count.
Revenues
decreased $4.8 million, or 57.1%, compared to the six months ended June 30, 2022. This decrease was primarily related to reductions in
services performed at Exemplar as well as the recognition of revenue in the first quarter of 2022 related to agreements for which revenue
was previously deferred that did not occur in 2023 of $1.0 million at Exemplar.
Total other
income, net, increased $5.2 million compared to the six months ended June 30, 2022. This was primarily due to reduced interest expense
associated with the Company’s convertible notes as they were retired in the second quarter of 2023, and increased interest income
due to higher interest rates on investments.
Loss from
continuing operations was $43.1 million, or $(0.18) per basic and diluted share, compared to loss from continuing operations of $50.0
million, or $(0.25) per basic and diluted share, in the six months ended June 30, 2022. The 2023 second quarter loss was lower than the
2023 first quarter loss primarily due to continued reductions in SG&A expenses.
###
Precigen: Advancing
Medicine with Precision™
Precigen (Nasdaq:
PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies
using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled
manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward
clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com
or follow us on Twitter @Precigen, LinkedIn
or YouTube.
UltraCAR-T®
UltraCAR-T is a multigenic
autologous CAR-T platform that utilizes Precigen's advanced non-viral Sleeping Beauty system to simultaneously express an antigen-specific
CAR to specifically target tumor cells, mbIL15 for enhanced in vivo expansion and persistence, and a kill switch to conditionally
eliminate CAR-T cells for a potentially improved safety profile. Precigen has advanced the UltraCAR-T platform to address the inhibitory
tumor microenvironment by incorporating a novel mechanism for intrinsic checkpoint blockade without the need for complex and expensive
gene editing techniques. UltraCAR-T investigational therapies are manufactured via Precigen's overnight manufacturing process using the
proprietary UltraPorator® electroporation system at the medical center and administered to patients only one day following
gene transfer. The overnight UltraCAR-T manufacturing process does not use viral vectors and does not require ex vivo activation
and expansion of T cells, potentially addressing major limitations of current T cell therapies.
UltraCAR-T®
Clinical Program
The UltraCAR-T platform
has shifted the autologous CAR-T manufacturing paradigm using an advanced non-viral multigene delivery system and an overnight, decentralized
manufacturing process for administration of autologous CAR-T cells one day after gene transfer to reduce vein-to-vein time. Precigen’s
UltraCAR-T platform is currently under clinical investigation for hematological and solid tumors, including a Phase 1/1b study of PRGN-3005
UltraCAR-T in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer (NCT03907527),
a Phase 1/1b study of PRGN-3006 UltraCAR-T in patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic
syndrome (MDS) (NCT03927261) and a Phase 1/1b study of PRGN-3007 UltraCAR-T incorporating PD-1
checkpoint inhibition in patients with ROR1-positive (ROR1+) hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma
(MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC)
malignancies (NCT05694364). PRGN-3006 UltraCAR-T has been granted Orphan
Drug Designation and Fast Track Designation in patients with AML by the US Food and
Drug Administration (FDA).
UltraCAR-T®
Library Approach
Precigen's UltraCAR-T
library approach is designed to transform the personalized cell therapy landscape for cancer patients. Precigen's goal is to develop
and validate a library of non-viral plasmids to target tumor-associated antigens. Enabled by design and manufacturing advantages of UltraCAR-T,
coupled with the capabilities of the UltraPorator® system, Precigen is working to empower cancer centers to deliver
personalized, autologous UltraCAR-T treatment with overnight manufacturing to any cancer patient. Based on the patient's cancer indication
and biomarker profile, one or more non-viral plasmids would be selected from the library to build a personalized UltraCAR-T treatment.
After initial treatment, this approach has the potential to allow for redosing of UltraCAR-T targeting the same or new tumor-associated
antigen(s) based on the treatment response and the changes in antigen expression of the patient's tumor. Precigen believes that the combination
of the advanced UltraVector® DNA construction platform and the ease of overnight manufacturing gives this library
approach a proprietary advantage over traditional T-cell therapies.
UltraPorator®
The UltraPorator
system is an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T
therapies and potentially represents a major advancement over current electroporation devices by significantly reducing the processing
time and contamination risk. The UltraPorator device is a high-throughput, semi-closed electroporation system for modifying T cells using
Precigen's proprietary non-viral gene transfer technology. UltraPorator is being utilized for clinical manufacturing of Precigen's investigational
UltraCAR-T therapies in compliance with current good manufacturing practices.
AdenoVerse™
Immunotherapy
Precigen's AdenoVerse
immunotherapy platform utilizes a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators,
and vaccine antigens designed to modulate the immune system. Precigen's gorilla adenovectors, part of the
AdenoVerse library,
have potentially superior performance characteristics as compared to current competition. AdenoVerse immunotherapies have been shown
to generate high-level and durable antigen-specific T-cell immune responses as well as an ability to boost these responses via repeat
administration. Superior performance characteristics and high yield manufacturing of AdenoVerse vectors leveraging UltraVector®
technology allows Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.
AdenoVerse™
Immunotherapy Clinical Program
Precigen’s
AdenoVerse immunotherapy platform is currently under clinical investigation in a Phase 1/2 study of PRGN-2009 AdenoVerse immunotherapy
alone or in combination with anti-PDL1/TGF-Beta Trap (bintrafusp alfa) in patients with HPV-associated cancers (NCT04432597),
including oropharyngeal squamous cell carcinoma (OPSCC), and a Phase 2 study of PRGN-2012 AdenoVerse
immunotherapy in patients with recurrent respiratory papillomatosis (RRP) (NCT04724980). PRGN-2012 has
been granted Orphan Drug Designation and Breakthrough
Therapy Designation in patients with RRP by the FDA. Additionally, the FDA has cleared the IND to initiate a Phase 2
study of PRGN-2009 AdenoVerse immunotherapy in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer.
For patients interested
in enrolling in NCI-led clinical studies, please call NCI's toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email
NCIMO_Referrals@mail.nih.gov, and/or visit the website: https://trials.cancer.gov.
Trademarks
Precigen, UltraCAR-T,
UltraPorator, AdenoVerse, UltraVector and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates.
Other names may be trademarks of their respective owners.
Cautionary Statement
Regarding Forward-Looking Statements
Some of the statements
made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations
and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's
business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise
of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in
this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations
change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information
on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from
those contained in the forward-looking statements, see the section entitled “Risk Factors“ in the Company's most recent Annual
Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor
Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
Precigen, Inc. and Subsidiaries |
Consolidated Balance Sheets |
(Unaudited) |
|
(Amounts
in thousands) | |
June
30, 2023 | |
December
31, 2022 |
Assets | |
| |
|
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 16,546 | | |
$ | 4,858 | |
Restricted cash | |
| - | | |
| 43,339 | |
Short-term investments | |
| 71,888 | | |
| 51,092 | |
Receivables | |
| | | |
| | |
Trade, net | |
| 1,354 | | |
| 978 | |
Other | |
| 13,052 | | |
| 12,826 | |
Prepaid expenses and other | |
| 2,792 | | |
| 5,066 | |
Total
current assets | |
| 105,632 | | |
| 118,159 | |
Long-term in investments | |
| 7,127 | | |
| - | |
Property, plant and equipment, net | |
| 6,574 | | |
| 7,329 | |
Intangible assets, net | |
| 42,656 | | |
| 44,455 | |
Goodwill | |
| 36,966 | | |
| 36,923 | |
Right-of-use assets | |
| 7,623 | | |
| 8,086 | |
Other assets | |
| 949 | | |
| 1,025 | |
Total
assets | |
$ | 207,527 | | |
$ | 215,977 | |
Liabilities and Shareholders' Equity | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 2,510 | | |
$ | 4,068 | |
Accrued compensation and benefits | |
| 4,820 | | |
| 6,377 | |
Other accrued liabilities | |
| 3,257 | | |
| 4,997 | |
Settlement and Indemnification Accrual | |
| 18,750 | | |
| 18,750 | |
Deferred revenue | |
| 15 | | |
| 25 | |
Current portion of long-term debt | |
| - | | |
| 43,219 | |
Current portion of lease liabilities | |
| 1,421 | | |
| 1,209 | |
Total
current liabilities | |
| 30,773 | | |
| 78,645 | |
Deferred revenue, net of current portion | |
| 1,818 | | |
| 1,818 | |
Lease liabilities, net of current portion | |
| 6,545 | | |
| 6,992 | |
Deferred tax liabilities | |
| 2,181 | | |
| 2,263 | |
Total
liabilities | |
| 41,317 | | |
| 89,718 | |
Shareholders' equity | |
| | | |
| | |
Common stock | |
| - | | |
| - | |
Additional paid-in capital | |
| 2,080,348 | | |
| 1,998,314 | |
Accumulated deficit | |
| (1,911,620 | ) | |
| (1,868,567 | ) |
Accumulated other comprehensive
loss | |
| (2,518 | ) | |
| (3,488 | ) |
Total
shareholders' equity | |
| 166,210 | | |
| 126,259 | |
Total
liabilities and shareholders' equity | |
$ | 207,527 | | |
$ | 215,977 | |
Precigen,
Inc. and Subsidiaries Consolidated
Statement of Operations |
(Unaudited) |
|
| |
Three months ended | |
Six months ended |
(Amounts in thousands, except share and
per share data) | |
June 30,
2023 | |
June 30,
2022 | |
June 30,
2023 | |
June 30,
2022 |
Revenues | |
| |
| |
| |
|
Product revenues | |
$ | 324 | | |
$ | 621 | | |
$ | 648 | | |
$ | 1,113 | |
Service revenues | |
| 1,438 | | |
| 2,213 | | |
| 2,965 | | |
| 7,146 | |
Other revenues | |
| 5 | | |
| 77 | | |
| 5 | | |
| 165 | |
Total revenues | |
| 1,767 | | |
| 2,911 | | |
| 3,618 | | |
| 8,424 | |
Operating Expenses | |
| | | |
| | | |
| | | |
| | |
Cost of products and services | |
| 1,697 | | |
| 1,811 | | |
| 3,224 | | |
| 3,505 | |
Research and development | |
| 11,874 | | |
| 11,954 | | |
| 24,037 | | |
| 23,755 | |
Selling, general and administrative | |
| 9,316 | | |
| 12,670 | | |
| 20,954 | | |
| 26,359 | |
Impairment of goodwill | |
| - | | |
| - | | |
| - | | |
| 482 | |
Impairment of other noncurrent assets | |
| - | | |
| 638 | | |
| - | | |
| 638 | |
Total operating expenses | |
| 22,887 | | |
| 27,073 | | |
| 48,215 | | |
| 54,739 | |
Operating loss | |
| (21,120 | ) | |
| (24,162 | ) | |
| (44,597 | ) | |
| (46,315 | ) |
Other Expense, Net | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (136 | ) | |
| (2,063 | ) | |
| (460 | ) | |
| (4,101 | ) |
Interest income | |
| 828 | | |
| 37 | | |
| 1,460 | | |
| 75 | |
Other income, net | |
| 44 | | |
| 40 | | |
| 424 | | |
| 238 | |
Total other income (expense), net | |
| 736 | | |
| (1,986 | ) | |
| 1,424 | | |
| (3,788 | ) |
Equity in net loss of affiliates | |
| - | | |
| - | | |
| - | | |
| (1 | ) |
Loss from continuing operations before income taxes | |
| (20,384 | ) | |
| (26,148 | ) | |
| (43,173 | ) | |
| (50,104 | ) |
Income tax benefit | |
| 65 | | |
| 89 | | |
| 120 | | |
| 147 | |
Loss from continuing operations | |
$ | (20,319 | ) | |
$ | (26,059 | ) | |
$ | (43,053 | ) | |
$ | (49,957 | ) |
Income from discontinued operations, net of income
taxes | |
| - | | |
| 8,424 | | |
| - | | |
| 13,071 | |
Net loss | |
$ | (20,319 | ) | |
$ | (17,635 | ) | |
$ | (43,053 | ) | |
$ | (36,886 | ) |
Net Loss per share | |
| | | |
| | | |
| | | |
| | |
Net loss from continuing operations per share, basic and diluted | |
$ | (0.08 | ) | |
$ | (0.13 | ) | |
$ | (0.18 | ) | |
$ | (0.25 | ) |
Net income from discontinued operations per share,
basic and diluted | |
| - | | |
| 0.04 | | |
| - | | |
| 0.07 | |
Net loss per share, basic and diluted | |
$ | (0.08 | ) | |
$ | (0.09 | ) | |
$ | (0.18 | ) | |
$ | (0.18 | ) |
Weighted average shares outstanding, basic and diluted | |
| 248,003,322 | | |
| 200,461,441 | | |
| 240,307,403 | | |
| 200,047,629 | |
Exhibit 99.2
Precigen Announces FDA Confirmation that the
Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
– FDA confirmed that the ongoing Phase 1/2 single arm study will
serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a BLA – |
– FDA agreed
on the required efficacy and safety endpoints that will support filing an accelerated approval BLA for licensure – |
– Enrollment and dosing in the ongoing Phase 2 portion of the
study is completed – |
– If approved, PRGN-2012 would potentially be the first therapeutic for the treatment of
RRP, a serious and difficult-to-treat orphan indication for which the current standard-of-care is repeated surgeries – |
GERMANTOWN, MD, August 9, 2023 –
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has
agreed that the ongoing Phase 1/2 single arm study (NCT04724980) of the first-in-class investigational
PRGN-2012 AdenoVerse™ immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP) will serve as pivotal
for the purpose of filing an accelerated approval request for licensure. The FDA also confirmed no additional randomized, placebo-controlled
trial will be required to support submission of a biologics license application (BLA). Based on the FDA guidance, the Company plans to
initiate a confirmatory study prior to submission of the BLA.
The
FDA has confirmed that the current primary endpoint for the ongoing Phase 1/2 study, which is Complete Response rate (percentage
of patients with no surgical interventions during the 12 months following treatment with PRGN-2012), along with an immunological surrogate
marker demonstrating an induction of HPV-specific T cell responses following PRGN-2012 treatment, is acceptable for the accelerated
approval request.
PRGN-2012 is an innovative therapeutic vaccine
with optimized antigen design that uses Precigen's gorilla adenovector technology, part of Precigen's proprietary AdenoVerse platform,
to elicit immune responses directed against cells infected with HPV 6 or HPV 11. Gorilla adenovectors have numerous advantages, including
the ability for repeat administration, the inability to replicate in vivo, which may improve safety, and the ability to deliver
a large genetic payload. The FDA granted PRGN-2012 Breakthrough Therapy Designation and Orphan
Drug Designation for the treatment of RRP.
Data from the Phase
1 portion of the study showed that 50% of adult RRP patients (who had ≥3 surgeries to treat the disease in the year
prior to treatment) were "surgery-free" (Complete Response) after PRGN-2012 treatment during the 12 month follow-up. All complete
responders continue to be surgery-free with a minimum follow-up of 18 months post-treatment. Precigen has
completed enrollment and dosing in the Phase 2 portion of the study (N=23) bringing the total number of enrolled patients to 35 at the
recommended Phase 2 dose. Patient follow up is currently ongoing and data collection is anticipated to be completed by the second quarter
of 2024.
"The eligibility of the Phase 1/2 study, which
has already been fully enrolled and dosed, as the pivotal study to support accelerated approval has the potential to significantly reduce
the product development time for PRGN-2012. We are thankful for the FDA’s decision, which underscores the importance of bringing
innovative approaches for the treatment of this serious and rare disease," said Helen Sabzevari, PhD, President and CEO of Precigen.
"I also want to thank the patients who participated in the study and our investigators, Dr. Clint T. Allen and Dr. Scott Norberg
from the National Institutes of Health, as well as the Precigen team.”
“The potential of this treatment is tremendously
exciting for RRP patients. The RRP community has only ever had one treatment option—surgery,” said Kim McClellan, President
of Recurrent Respiratory Papillomatosis Foundation. “The potential to eliminate even one surgery and improve the quality of our
lives would have a profound impact on those living with RRP.”
###
Precigen: Advancing
Medicine with Precision™
Precigen (Nasdaq:
PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies
using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled
manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward
clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com
or follow us on Twitter @Precigen, LinkedIn
or YouTube.
About Recurrent
Respiratory Papillomatosis (RRP)
Recurrent respiratory
papillomatosis (RRP) is a rare, difficult-to-treat and sometimes fatal neoplastic disease of the upper and lower respiratory tracts that
is caused by infection with HPV 6 or HPV 11.1-4 RRP is classified based on age of onset as juvenile or adult. Juvenile-onset
disease has an incidence of 4 per 100,000 and adult-onset RRP has an incidence of 2 to 3 per 100,000. Currently there is no cure for
RRP and the current standard-of-care is repeated endoscopic debulking with ablation or excision of papillomatous lesions.3,4
Recurrence of papilloma after surgical removal is very common and repeated procedures are required to debulk and monitor the disease,
which exposes patients to anesthetic and surgical risks, and emotional distress. RRP morbidity and mortality results from the effects
of papilloma mass on the vocal cords, trachea, and lungs, which may cause voice changes, stridor, airway occlusion, loss of lung volume,
and/or post-obstructive pneumonia.5 Although rare, one to three percent of RRP cases can transform into invasive squamous
cell carcinoma.6,7
AdenoVerse™ Immunotherapy
Clinical Program
Precigen's AdenoVerse
immunotherapy platform is currently under clinical investigation in a Phase 1/2 study of PRGN-2009 AdenoVerse immunotherapy alone or
in combination with anti-PDL1/TGF-Beta Trap (bintrafusp alfa) in patients with HPV-associated cancers (NCT04432597),
including oropharyngeal squamous cell carcinoma (OPSCC) and a Phase 1/2 study of PRGN-2012 AdenoVerse immunotherapy in patients
with recurrent respiratory papillomatosis (RRP) (NCT04724980). PRGN-2012
has been granted Orphan Drug Designation and Breakthrough
Therapy Designation in patients with RRP by the FDA. Additionally, the FDA has cleared the IND to initiate a Phase 2
study of PRGN-2009 AdenoVerse immunotherapy in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer.
For patients interested in enrolling in NCI-led clinical studies, please call NCI's toll-free number 1-800-4-Cancer (1-800-422-6237)
(TTY: 1-800-332-8615), email NCIMO_Referrals@mail.nih.gov,
and/or visit the website: https://trials.cancer.gov.
AdenoVerse™
Immunotherapy
Precigen's AdenoVerse
immunotherapy platform utilizes a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators,
and vaccine antigens designed to modulate the immune system. Precigen's gorilla adenovectors, part of the AdenoVerse library, have potentially
superior performance characteristics as compared to current competition. AdenoVerse immunotherapies have been shown to generate high-level
and durable antigen-specific T-cell immune responses as well as an ability to boost these responses via repeat administration. Superior
performance characteristics and high yield manufacturing of AdenoVerse vectors leveraging UltraVector® technology allows
Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.
Trademarks
Precigen, AdenoVerse,
UltraVector and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks
of their respective owners.
Cautionary Statement
Regarding Forward-Looking Statements
Some of the statements
made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations
and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's
business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise
of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in
this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations
change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information
on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from
those contained in the forward-looking statements, see the section entitled “Risk Factors“ in the Company's most recent Annual
Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
References
| 1 | Mounts, P et
al. (1982). "Viral etiology of juvenile- and adult-onset squamous papilloma of the
larynx." Proc Natl Acad Sci U S A 79(17): 5425-5429. |
| 2 | Smith, E et
al. (1993). "Human papillomavirus infection in papillomas and nondiseased respiratory
sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction."
Arch Otolaryngol Head Neck Surg 119(5): 554-557. |
| 3 | Derkay, CS
et al. (2008). "Recurrent respiratory papillomatosis: a review." Laryngoscope
118(7): 1236-1247. |
| 4 | Derkay, CS
et al. (2019). "Update on Recurrent Respiratory Papillomatosis." Otolaryngol
Clin North Am 52(4): 669-679. |
| 5 | Seedat, RY
(2020). "Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management
- A Developing Country Review." Pediatric Health Med Ther 11: 39-46. |
| 6 | Dedo, HH et
al. (2001). "CO(2) laser treatment in 244 patients with respiratory papillomas."
Laryngoscope 111(9): 1639-1644. |
| 7 | Silver, RD
et al. (2003). "Diagnosis and management of pulmonary metastasis from recurrent
respiratory papillomatosis." Otolaryngol Head Neck Surg 129(6): 622-629. |
Investor Contact:
Steven M. Harasym
Vice President, Investor
Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Precigen (NASDAQ:PGEN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Precigen (NASDAQ:PGEN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024